FINWIRES · TerminalLIVE
FINWIRES

$TBPH

4 stories mentioning TBPHUpdated 44d ago

Every FINWIRES story that references TBPH, newest first.

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) gaining 0.2%.The iShares Biotechnology ETF (IBB) rose 0.9%.In corporate news, Zymeworks (ZYME) has agreed to buy Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 0.6%, and Theravance fell 3.2%.Abbott Laboratories (ABT) shares were down 1.3%. The Wall Street Journal reported Sunday the company will not face criminal charges after the US Department of Justice closed a years-long investigation into its baby formula operations.QuidelOrtho (QDEL) shares surged 34%. The company is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday.Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a note Monday. BofA downgraded Alkermes to underperform from neutral with a price target of $38. Shares were down 4.7%.

$ABT$ALKS$QDEL$TBPH$ZYME
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) rose 0.4%.In corporate news, Abbott Laboratories (ABT) shares were down 0.6%. The Wall Street Journal reported Sunday the company will not face criminal charges after the US Department of Justice closed a years-long investigation into its baby formula operations.Zymeworks (ZYME) has agreed to buy Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 1%, and Theravance fell 2.3%.QuidelOrtho (QDEL) shares surged 34%. The company is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday.

$ABT$QDEL$TBPH$ZYME
Research

BTIG Downgrades Theravance Biopharma to Neutral From Buy

BTIG Downgrades Theravance Biopharma to Neutral From Buy

$TBPH
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Monday

Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) advancing by 0.3%.BridgeBio Pharma (BBIO) stock was up 3.8% after the company said it has met the primary endpoint in a late-stage trial of the oral drug infigratinib, for the treatment of children living with achondroplasia, or bone dwarfism.Viridian Therapeutics (VRDN) shares were up more than 8% after the company said Lumvoa received approval from the US Food and Drug Administration to treat thyroid eye disease, an autoimmune disease.Zymeworks (ZYME) has signed a definitive agreement to acquire Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 5% and Theravance Biopharma stock fell 3.5% pre-bell.

$BBIO$IBB$TBPH$VRDN$XLV$ZYME

Track with the FINWIRES app suite